Saketkoo et al raise interesting questions related to findings in our recently published study of patients with systemic sclerosis-related interstitial lung disease [SSc-ILD] (1) . They underline the fact that forced vital capacity (FVC) did not differ between patients with combined pulmonary fibrosis and emphysema (CPFE) and those without emphysema, despite more extensive SSc-ILD in the former. However, the suggestion that this discrepancy might represent relative preservation of FVC due to emphysema was not supported by other analyses. On multivariate analysis, the presence of emphysema had no independent effect on FVC levels, once the extent of fibrosis had been taken into account.
An additional unpublished analysis (prompted by the thoughtful comments of Saketkoo et al) shows no linkage between the extent of emphysema and preservation of FVC levels in the 41 patients with CPFE. For the moment, these apparent contradictions are unexplained.
We agree strongly that there is a need to examine the impact of concurrent emphysema on serial change in FVC, used as the primary end-point in recent trials in SSc-ILD (2) (3) (4) .
Conflicting information exists on serial changes in FVC and diffusing capacity for carbon monoxide (DLCO) in patients with idiopathic pulmonary fibrosis (IPF) and CPFE. In one cohort, the 3-year change in both variables did not differ between IPF and IPF-CPFE (5), but in another series, patients with IPF-CPFE were characterized by less decline in FVC and DLco than that observed in IPF patients without emphysema (6) In a well-defined pharmaceutical IPF cohort, patients with IPF and CPFE had significantly lower rate of decline of FVC than patients with IPF (7) . In line with the suggestion by Saketkoo et al, we are close to completion of analyses evaluating whether baseline and serial changes in FVC are predictive of mortality in the subgroups of patients with and without emphysema.
We also agree that the use of spirometric values as a screening tool for SSc-ILD may be misleading (although the question of screening for ILD was not addressed in our recent manuscript). Alternative screening strategies might be a) HRCT at baseline in all SSc patients; and b) selection of SSc patients to undergo HRCT, based on the integration of clinical, physiologic and chest radiographic features. We are not aware of data that establish that either strategy is preferable.
With regard to PH-related issues, we must plead a limitation common to virtually all studies Future research studies should explore whether a combination of these markers might replace the FVC/DLco ratio in CPFE or even in SSc-ILD in general.
